Breast Cancer Clinical Trial Using 9 Peptides from Her-2/neu, CEA, & CTA + poly-ICLC

- The folks at University of Virginia are studying the effects of 9 Peptides from Her-2/neu, CEA, & CTA + poly-ICLC on Breast Cancer in individuals ages 18 years and older. This clinical trial is slated to start July 2012.

Emily Allred, PhD
Overall Study Contact Info
StatusName Contact Phone
RecruitingEmily Allred, PhDEH4M@virginia.edu434-982-1902

This study is officially titled, "A Pilot Study of the Immunogenicity of a 9-Peptide Breast Cancer Vaccine Plus Poly-ICLC in Stage IB-IIIA Breast Cancer."


University of Virginia Health System

Charlottesville, Virginia - Recruiting

For more study details, please visit this link to record, which is the source of this webpage.